Imagine a tiny sensor, the size of a cent coin, that sits under your skin and tells your doctor exactly how much medicine is in your blood in real time. Instead of taking blood samples and sending them to a lab, the data goes straight to a smartphone. When the treatment is over, the sensor simply melts away safely inside your body, so you don't need a second surgery to remove it.
Current chemotherapy monitoring relies on external blood tests that provide only a snapshot of drug levels. This lacks the real-time, localized data needed to optimize dosing and avoid toxicity.
A bioresorbable sensing system including molecularly imprinted polymers (d-MIPs) for doxorubicin detection, thermoresponsive hydrogels for protection, and HSA-agarose optical fibers.
If you are a drug developer dealing with unpredictable patient responses to doxorubicin — this project developed bioresorbable sensors that detect drug levels from 0.1 to 10 µg mL⁻¹. This allows for fine-tuning the dose at the tumor site to increase patient survival rates.
If you are a device manufacturer dealing with the risks of surgical retrieval and infection — this project developed a system with on-demand degradation. The device is fully RESORBed using an external temperature-trigger, eliminating the need for retrieval surgery.
If you are a digital health provider dealing with the gap between clinic visits and real-time data — this project developed a sensor that communicates wirelessly with a smartphone. This transforms healthcare from single-point testing to dynamic, personalized medical feedback.
Based on available project data, there is no specific pricing or unit cost mentioned for the sensing system.
The project focuses on demonstrating fabrication and operation in animal models; industrial scaling details are not provided in the current report.
Based on available project data, specific patent numbers or licensing terms are not listed, though the project developed specific d-MIPs and hydrogel formulations.
The project demonstrated stability under physiological conditions for 12 weeks or more.
The system is implanted beneath the skin and is designed to be the size of 1 EuroCent.
The consortium is heavily academic, consisting of 7 partners from 4 countries (FR, IT, PT, UK). With 6 universities and 1 research organization, there is a 0% industry ratio, indicating the project is currently in a high-research phase rather than a commercialization phase.
Contact Università di Pisa
Contact us to find industrial partners for the commercialization of bioresorbable sensors.
